BGT226 is in phase I/II clinical trials for the treatment of advanced solid tumors, such as breast, head and neck, endothelial cells and lung cancer [11, 18, 26–29] and this is the first work showing the in vitro activity of this PI3K/Akt signaling pathway inhibitor in HCC cells. This evidence concerns the gene PIK3CA and hepatocellular carcinoma.